On February 14, 2025, Ono Pharmaceuticals secured FDA approval for vimseltinib, a therapy for tenosynovial giant cell tumor (TGCT), which will be marketed as ROMVIMZA. This approval places Ono in direct competition with another Japanese pharmaceutical company, Daiichi Sankyo, in the TGCT...
Read More Details
Finally We wish PressBee provided you with enough information of ( Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance .. DelveInsight )
Also on site :
- Sen. Thom Tillis Announces Retirement After Trump Threatens Primary Race
- Parvati Shallow Reveals How 'The Traitors' Led to Her Coming Out
- Marshall says he believes Trump megabill ‘will help shrink the debt’